Examkin

Soru

Zorluk: ZorEnd-of-Life and Palliative Care

A 61-year-old woman is evaluated in the hospital for altered mental status. She was admitted 3 days ago for management of acute kidney injury secondary to ureteral obstruction. Her past medical history is significant for advanced cervical cancer, and her severe pelvic pain has been well controlled at home with high-dose extended-release oral morphine.

Today, the patient's partner reports that she has become progressively confused and agitated overnight. On examination, the patient is somnolent but groans and withdraws to light touch, demonstrating severe tactile allodynia. She frequently exhibits involuntary, rapid muscle jerks in all four extremities. Vital signs show a temperature of 37.1°C (98.8°F), blood pressure of 110/70 mmHg, heart rate of 98/min, and respiratory rate of 18/min. Oxygen saturation is 97% on room air. Laboratory studies show a serum creatinine of 3.8 mg/dL (baseline 1.1 mg/dL). Which of the following is the most appropriate next step in the management of this patient's symptoms?

  1. A
    Administer intravenous haloperidol and maintain the current morphine dose
  2. B
    Rotate to an equianalgesic dose of extended-release oxycodone
  3. Discontinue morphine, provide intravenous hydration, and rotate to a reduced dose of intravenous fentanylCevap
  4. D
    Administer intravenous naloxone
  5. E
    Initiate palliative sedation with a continuous midazolam infusion

Cevap

Discontinue morphine, provide intravenous hydration, and rotate to a reduced dose of intravenous fentanyl
The patient is experiencing opioid-induced neurotoxicity (OIN), characterized by altered mental status, tactile allodynia (hyperalgesia), and myoclonus. This condition frequently occurs when patients on high doses of morphine develop acute kidney injury. Morphine is hepatically metabolized into morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), which are renally excreted. In acute kidney injury, M3G accumulates and crosses the blood-brain barrier, causing neurotoxic effects. The definitive management of OIN is to discontinue the offending opioid, provide intravenous hydration to promote renal clearance of the metabolites (if the patient's volume status permits), and rotate to a structurally dissimilar opioid. Fentanyl and methadone are the preferred opioids in severe renal impairment because they lack active neurotoxic metabolites that rely on renal clearance. Due to incomplete cross-tolerance, the initial dose of the new opioid should be appropriately reduced.

Adım Adım Çözüm

1
Identify the patient's acute clinical syndrome.
The patient presents with somnolence, tactile allodynia, confusion, and multifocal myoclonic jerks with a normal respiratory rate.
These findings represent the classic triad of opioid-induced neurotoxicity (OIN): hyperalgesia, myoclonus, and delirium.
2
Determine the underlying etiology for the syndrome.
The patient has a severely elevated serum creatinine (3.8 mg/dL) indicating acute kidney injury.
Morphine is hepatically metabolized into active metabolites (morphine-3-glucuronide) that rely on renal clearance. In renal failure, these neurotoxic metabolites accumulate rapidly.
3
Select the appropriate therapeutic intervention.
Discontinue the offending agent (morphine), provide intravenous hydration to facilitate clearance, and rotate to an opioid that is safe in renal impairment (such as fentanyl).
This strategy directly treats the underlying cause (metabolite accumulation) while safely maintaining necessary analgesia.

Anahtar Kavram

Opioid-induced neurotoxicity presents with hyperalgesia, myoclonus, and delirium, frequently triggered by the accumulation of active morphine metabolites (M3G) in the setting of acute kidney injury. Definitive management requires hydration and opioid rotation to a safer alternative like fentanyl or methadone.
Bu soruyu puanla

Konular

End-of-Life and Palliative Care

Bu konudan daha fazla soru